Another CAR-T First: Yescarta Wins Lymphoma Funding In England
Executive Summary
Gilead has agreed a confidential deal with NHS England under which its pioneering CAR-T therapy Yescarta will be provided to adult lymphoma patients under the Cancer Drugs Fund. The funding decision gives Yescarta an edge in the lymphoma market over Kymriah, the other EU-authorized CAR-T treatment.
You may also be interested in...
New Thinking Needed On Reimbursement Of Cell And Gene Therapies
One-off payment deals for expensive cell and gene therapies cannot be the way forward for healthcare systems aiming for the systematic uptake of these products.
UK: Funding For Second Kymriah Indication After Talks And Price Cut
UK HTA body NICE says a second indication for Novartis’s groundbreaking CAR-T cell therapy Kymriah should be covered under the Cancer Drugs Fund.
CAR-T Funding: It's (Nearly) All About The Price In The UK
Gilead’s Yescarta and Novartis’s Kymriah are pioneering and effective approaches to the treatment of serious cancers, but in the UK they have had mixed fortunes at the hands of NICE, the body that decides whether new therapies are value for money and should be available under the national health service. Both companies will probably have to cut their asking price to secure routine funding